SCHEMBL2009899

SCHEMBL2009899

CCOC(=O)COc1ccc(C(=O)CN)c(O)c1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
NPSR1 Q6W5P4 4/20 0.51
HPGD P15428 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 1/20 0.51
CASP1 P29466 1/20 0.51
HSD17B10 Q99714 1/20 0.51
CASP3 P42574 1/20 0.46
CASP7 P55210 1/20 0.46
CASP9 P55211 1/20 0.46
ABCB1 P08183 1/20 0.43
ESR1 P03372 1/20 0.42
USP2 O75604 1/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
CYP2C9 P11712 2/20 0.40
HIF1A Q16665 2/20 0.40
ABCC3 O15438 1/20 0.40
PLIN1 O60240 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2009124 0.88 ALDH1A1 (0.50) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL2008203 0.88 CASP3 (0.47) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL2008184 0.87 CASP3 (0.46) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL2010881 0.86 ALDH1A1 (0.53) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL2012527 0.86 CASP3 (0.45) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL2009189 0.84 PPARG (0.48) MEN1KMT2ACASP3CASP7CASP9
SCHEMBL2007749 0.83 CASP3 (0.43) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL2008148 0.80 ALDH1A1 (0.43) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL2013912 0.78 HPGD (0.53) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL2009367 0.78 GAA (0.46) ALDH1A1NPSR1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 ALDH1A1 2548/4885NPSR1 340/4885HPGD 1551/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 ALDH1A1 2548/4885NPSR1 340/4885HPGD 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.